Expand into regulated annotation domains.
Regulated data annotation means human annotators see sensitive records. That creates exposure. Integral bounds, documents, and assesses that exposure so you can expand into healthcare, financial, and clinical annotation without taking on unmanaged privacy risk.
Annotation as a privacy boundary
Every record a human annotator views is a data access event. In regulated domains, each event carries re-identification risk that must be assessed and documented. Without that assessment, annotation platforms cannot credibly serve healthcare, clinical, or financial data owners.
Integral provides the assessment and documentation layer that makes regulated annotation defensible. Human exposure is bounded at the process level and assessed at the dataset level. The result is documentation that data owners and their regulators trust.
What Integral delivers
Bounded human exposure
Assessment defines what annotators can see, under what conditions, and with what safeguards. Exposure is documented at the process level and the dataset level.
Documentation data owners require
Data owners in regulated industries require evidence of how their data is handled during annotation. Integral produces that evidence with methodology provenance and signed assessment.
Win builder business in regulated domains
AI builders sourcing regulated training data need annotation partners with defensible privacy postures. Integral documentation differentiates your platform in procurement.
How it works
Define the annotation scope
Integral maps the data types annotators will access, the annotation task, the access conditions, and the regulatory context.
Assess under defined assumptions
Qualified experts assess re-identification risk given the annotation workflow. The assessment accounts for what annotators see and how records are exposed.
Engineer process-level safeguards
Privacy engineering is applied at the process level to bound exposure. Controls are documented alongside the dataset-level determination.
Deliver documentation to data owners
Data owners receive a complete evidence package covering the assessment, the process safeguards, and the re-assessment schedule.
What teams say
“Integral provided the expertise and structure we needed to turn complex, regulated healthcare data into actionable insights. Their team is consistently responsive, highly knowledgeable, and deeply collaborative.”
Frequently asked questions
What regulated data types can our annotators work with after assessment?
Any regulated data type where re-identification risk can be assessed and bounded: clinical records, claims data, consumer health data, financial records, and other sensitive datasets.
Does this replace our existing annotation security controls?
No. Integral adds a privacy assessment and documentation layer on top of your existing security controls. The determination evaluates re-identification risk; your platform maintains access controls, encryption, and operational security.
How do we demonstrate defensibility to data owners?
Integral delivers an end-to-end evidence package: assessment scope, process-level safeguards, remediation detail, methodology provenance, and a re-assessment schedule. The package is designed for data owner procurement and regulatory review.
Can Integral assess RL (reinforcement learning) environments?
Yes. RL environments where human evaluators interact with regulated data can be assessed and documented. The engagement is scoped to the specific interaction model and data exposure.
